Simultaneous Imaging and Drug Delivery for Prostate Cancer Theranostics

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1046831

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Prostate cancer (PC) is the most common cancer in men over 50. The answers to the key questions in advanced PC (Who to treat, and how to treat: loco-regionally or systemically?) rest with clinical staging – something that has hitherto been very imprecise. We have generated a highly-sensitive 19F-molecular imaging agent which could help resolve both questions and create a targeted therapy, diminishing the burden of harm of today’s therapies by using nanoparticles to diagnose and treat PC.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2016

Funding Scheme: Project Grants

Funding Amount: $565,205.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer staging | diagnosis | drug delivery | imaging | prostate cancer

Related Links